Skip Navigation LinksHome > October 2012 - Volume 16 - Issue 4 > Prevalence of Human Papillomavirus Types in Invasive Vulvar...
Journal of Lower Genital Tract Disease:
doi: 10.1097/LGT.0b013e3182472947
Basic Science

Prevalence of Human Papillomavirus Types in Invasive Vulvar Cancers and Vulvar Intraepithelial Neoplasia 3 in the United States Before Vaccine Introduction

Gargano, Julia W. PhD1,2; Wilkinson, Edward J. MD3; Unger, Elizabeth R. PhD, MD2; Steinau, Martin PhD2; Watson, Meg MPH4; Huang, Youjie DrPH, MD5; Copeland, Glenn MBA6; Cozen, Wendy DO, MPH7; Goodman, Marc T. PhD, MPH8; Hopenhayn, Claudia PhD, MPH9; Lynch, Charles F. PhD, MD10; Hernandez, Brenda Y. PhD8; Peters, Edward S. ScD, DMD11; Saber, Maria Sibug MD7; Lyu, Christopher W. MPA12; Sands, Lauren A. BA2; Saraiya, Mona MD, MPH5

Collapse Box

Abstract

Objective: The study aimed to determine the baseline prevalence of human papillomavirus (HPV) types in invasive vulvar cancer (IVC) and vulvar intraepithelial neoplasia 3 (VIN 3) cases using data from 7 US cancer registries.

Materials and Methods: Registries identified eligible cases diagnosed in 1994 to 2005 and requested pathology laboratories to prepare 1 representative block for HPV testing on those selected. Hematoxylin-eosin–stained sections preceding and following those used for extraction were reviewed to confirm representation. Human papillomavirus was detected using L1 consensus polymerase chain reaction (PCR) with PGMY9/11 primers and type-specific hybridization, with retesting of samples with negative and inadequate results with SPF10 primers. For IVC, the confirmatory hematoxylin-eosin slides were re-evaluated to determine histological type. Descriptive analyses were performed to examine distributions of HPV by histology and other factors.

Results: Human papillomavirus was detected in 121/176 (68.8%) cases of IVC and 66/68 (97.1%) cases of VIN 3 (p < .0001). Patients with IVC and VIN 3 differed by median age (70 vs 55 y, p = .003). Human papillomavirus 16 was present in 48.6% of IVC cases and 80.9% of VIN 3 cases; other high-risk HPV was present in 19.2% of IVC cases and 13.2% of VIN 3 cases. Prevalence of HPV differed by squamous cell carcinoma histological subtype (p < .0001) as follows: keratinizing, 49.1% (n = 55); nonkeratinizing, 85.7% (n = 14), basaloid, 92.3% (n = 14), warty 78.2% (n = 55), and mixed warty/basaloid, 100% (n = 7).

Conclusions: Nearly all cases of VIN 3 and two thirds of IVC cases were positive for high-risk HPV. Prevalence of HPV ranged from 49.1% to 100% across squamous cell carcinoma histological subtypes. Given the high prevalence of HPV in IVC and VIN 3 cases, prophylactic vaccines have the potential to decrease the incidence of vulvar neoplasia.

©2012The American Society for Colposcopy and Cervical Pathology

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.